First Participants Dosed in a Phase 1 Clinical Trial of COR388

First Participants Dosed in a Phase 1 Clinical Trial of COR388
The pharmaceutical company Cortexyme announced that the first group of participants has been dosed in the Phase 1 clinical trial of its lead compound, COR388, for the treatment of Alzheimer’s disease. Because no new successful developments have emerged in Alzheimer’s therapeutics in the last 15 years, researchers have been trying to discover new and innovative ways

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. Leanne Jack says:

    Can you advise which country this study is being undertaken in please? Also, is this trial likely to be undertaken in Brisbane, Australia please? I look forward to hearing from you. Thanking you. Leanne

Leave a Comment

Your email address will not be published. Required fields are marked *